MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Over three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now classified based on molecular phenotype and not purely on histological attr...

Descripción completa

Detalles Bibliográficos
Autores principales: Felder, Mildred, Kapur, Arvinder, Gonzalez-Bosquet, Jesus, Horibata, Sachi, Heintz, Joseph, Albrecht, Ralph, Fass, Lucas, Kaur, Justanjyot, Hu, Kevin, Shojaei, Hadi, Whelan, Rebecca J, Patankar, Manish S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046138/
https://www.ncbi.nlm.nih.gov/pubmed/24886523
http://dx.doi.org/10.1186/1476-4598-13-129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046138/
https://www.ncbi.nlm.nih.gov/pubmed/24886523
http://dx.doi.org/10.1186/1476-4598-13-129

Ejemplares similares